Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares. Century is conducting the Phase I CALiPSO-1 study of CNTY-101 in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis patients. Recent Phase I ELiPSE-1 data showed 1.0B CNTY-101 cells achieved ORR of 83%, including 2 CRs, 3 PRs, and 1 SD in B cell lymphoma patients with no GvHD or DLTs, the firm notes. Century expects to update ELiPSE-1 data in mid-2025. Bristol Myers (BMY) recently terminated the Century collaboration for CNTY-104 for AML and CNTY-106 for multiple myeloma effective March 12, 2025 due to portfolio prioritization, adds Piper.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Faces Termination of BMS Agreement
- Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults
- Century Therapeutics price target lowered to $11 from $17 at Chardan
- Century Therapeutics price target lowered to $5 from $9 at H.C. Wainwright
- Century Therapeutics Reports Q3 Results & Strategic Updates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
